Article (Scientific journals)
Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.
Zegels, Brigitte; Crozes, P.; Uebelhart, D. et al.
2013In Osteoarthritis and Cartilage, 21 (1), p. 22-27
Peer Reviewed verified by ORBi
 

Files


Full Text
Equivalence of a single dose (1200mg).pdf
Publisher postprint (563.42 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] OBJECTIVE: Evaluation of the efficacy and safety of a single oral dose of a 1200 mg sachet of chondroitin 4&6 sulfate (CS 1200) vs three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400) (equivalence study) and vs placebo (superiority study) during 3 months, in patients with knee osteoarthritis (OA). DESIGN: Comparative, double-blind, randomized, multicenter study, including 353 patients of both genders over 45 years with knee OA. Minimum inclusion criteria were a Lequesne index (LI) >/= 7 and pain >/= 40 mm on a visual analogue scale (VAS). LI and VAS were assessed at baseline and after 1-3 months. Equivalence between CS was tested using the per-protocol procedure and superiority of CS vs placebo was tested using an intent-to-treat procedure. RESULTS: After 3 months of follow-up, no significant difference was demonstrated between the oral daily single dose of CS 1200 formulation and the three daily capsules of CS 400. Patients treated with CS 1200 or CS 3*400 were significantly improved compared to placebo after 3 months of follow-up in terms of LI (<0.001) and VAS (P < 0.01). No significant difference in terms of security and tolerability was observed between the three groups. CONCLUSION: This study suggests that a daily administration of an oral sachet of 1200 mg of chondroitin 4&6 sulfate allows a significant clinical improvement compared to a placebo, and a similar improvement when compared to a regimen of three daily capsules of 400 mg of the same active ingredient.
Disciplines :
General & internal medicine
Author, co-author :
Zegels, Brigitte ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Crozes, P.
Uebelhart, D.
Bruyère, Olivier  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
REGINSTER, Jean-Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.
Publication date :
2013
Journal title :
Osteoarthritis and Cartilage
ISSN :
1063-4584
eISSN :
1522-9653
Publisher :
W.B. Saunders, London, United Kingdom
Volume :
21
Issue :
1
Pages :
22-27
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Available on ORBi :
since 25 January 2013

Statistics


Number of views
44 (9 by ULiège)
Number of downloads
2 (2 by ULiège)

Scopus citations®
 
46
Scopus citations®
without self-citations
33
OpenCitations
 
43

Bibliography


Similar publications



Contact ORBi